


Objective: To evaluate safety/tolerability, anti-tumor activity, and RP2D of telaglenastat in combination with everolimus or cabozantinib in patients with mRCC



Tumor response (RECIST 1.1) assessed every 8 weeks

BID, twice daily; cc, clear cell; pap, papillary; PO, per oral; QD, once daily; RP2D, recommended phase 2 dose

Figure S2. Study Schema